Approved indications for use of novel oral anticoagulants
| Drug/region . | Prevention of stroke/systemic embolism in nonvalvular atrial fibrillation . | Prevention of VTE after hip/knee replacement surgery . | Treatment of acute VTE . | Prevention of VTE recurrence . |
|---|---|---|---|---|
| Dabigatran | ||||
| United States | ✓ | |||
| Canada | ✓ | ✓ | ||
| Europe | ✓ | ✓ | ||
| Rivaroxaban | ||||
| United States | ✓ | ✓ | ✓ | ✓ |
| Canada | ✓ | ✓ | ✓ | ✓ |
| Europe | ✓ | ✓ | ✓ | ✓ |
| Apixaban | ||||
| United States | ✓ | |||
| Canada | ✓ | ✓ | ||
| Europe | ✓ | ✓ |
| Drug/region . | Prevention of stroke/systemic embolism in nonvalvular atrial fibrillation . | Prevention of VTE after hip/knee replacement surgery . | Treatment of acute VTE . | Prevention of VTE recurrence . |
|---|---|---|---|---|
| Dabigatran | ||||
| United States | ✓ | |||
| Canada | ✓ | ✓ | ||
| Europe | ✓ | ✓ | ||
| Rivaroxaban | ||||
| United States | ✓ | ✓ | ✓ | ✓ |
| Canada | ✓ | ✓ | ✓ | ✓ |
| Europe | ✓ | ✓ | ✓ | ✓ |
| Apixaban | ||||
| United States | ✓ | |||
| Canada | ✓ | ✓ | ||
| Europe | ✓ | ✓ |
VTE, venous thromboembolism.